Breaking News

Tuesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Inspire Medical announces FDA approval for pediatric patients with Down Syndrome » 08:09
03/21/23
03/21
08:09
03/21/23
08:09
INSP

Inspire Medical

$247.86 /

+0.79 (+0.32%)

Inspire Medical Systems…

Inspire Medical Systems announced that it has received approval from the Food and Drug Administration, FDA, to offer Inspire therapy to pediatric patients with Down syndrome. "Since our first FDA approval in 2014, the research team at Mass Eye and Ear, led by Dr. Christopher Hartnick, have pioneered the use of Inspire in this important group of people and we are thrilled to announce this most impactful approval on World Down Syndrome Day," said Tim Herbert, President and Chief Executive Officer of Inspire. "We acknowledge and appreciate the persistence of Dr. Hartnick's team, as well as the teams at the many participating institutions, to collect the necessary clinical evidence to support the FDA approval. We would also like to thank the LuMind IDSC Down Syndrome Foundation for their support of our FDA application. Inspire intends to immediately begin educating healthcare providers across the U.S. about the benefits of Inspire therapy for children with Down syndrome." Inspire has been prescribed to adults with Down syndrome for several years, but previously only to patients who were at least 18 years of age. Approval of the pediatric population with Down syndrome will include OSA patients who are at least 13 years old, with an apnea hypopnea index between 10 and 50, and do not have the ability to benefit from CPAP.

ShowHide Related Items >><<
INSP Inspire Medical
$247.86 /

+0.79 (+0.32%)

INSP Inspire Medical
$247.86 /

+0.79 (+0.32%)

02/08/23 Lake Street
Inspire Medical price target raised to $305 from $250 at Lake Street
02/08/23 Truist
Inspire Medical price target raised to $330 from $310 at Truist
02/08/23 Piper Sandler
Inspire Medical price target raised to $305 from $300 at Piper Sandler
01/31/23 Truist
Inspire Medical price target raised to $310 from $308 at Truist
INSP Inspire Medical
$247.86 /

+0.79 (+0.32%)

  • 12
    Aug
INSP Inspire Medical
$247.86 /

+0.79 (+0.32%)

Over a week ago
Hot Stocks
Inspire Medical receives countrywide reimbursement approval in Belgium » 17:25
03/09/23
03/09
17:25
03/09/23
17:25
INSP

Inspire Medical

$243.07 /

-10.46 (-4.13%)

Inspire Medical announced…

Inspire Medical announced that it has received countrywide reimbursement approval in Belgium, effective immediately, at rates consistent with other countries around the world.

ShowHide Related Items >><<
INSP Inspire Medical
$243.07 /

-10.46 (-4.13%)

INSP Inspire Medical
$243.07 /

-10.46 (-4.13%)

02/08/23 Lake Street
Inspire Medical price target raised to $305 from $250 at Lake Street
02/08/23 Truist
Inspire Medical price target raised to $330 from $310 at Truist
02/08/23 Piper Sandler
Inspire Medical price target raised to $305 from $300 at Piper Sandler
01/31/23 Truist
Inspire Medical price target raised to $310 from $308 at Truist
INSP Inspire Medical
$243.07 /

-10.46 (-4.13%)

  • 12
    Aug
INSP Inspire Medical
$243.07 /

-10.46 (-4.13%)

Conference/Events
Inspire Medical management to meet with Truist » 04:55
03/02/23
03/02
04:55
03/02/23
04:55
INSP

Inspire Medical

$263.70 /

+3.695 (+1.42%)

Meetings to be held in…

Meetings to be held in New York March 1-2 hosted by Truist.

ShowHide Related Items >><<
INSP Inspire Medical
$263.70 /

+3.695 (+1.42%)

INSP Inspire Medical
$263.70 /

+3.695 (+1.42%)

02/08/23 Lake Street
Inspire Medical price target raised to $305 from $250 at Lake Street
02/08/23 Truist
Inspire Medical price target raised to $330 from $310 at Truist
02/08/23 Piper Sandler
Inspire Medical price target raised to $305 from $300 at Piper Sandler
01/31/23 Truist
Inspire Medical price target raised to $310 from $308 at Truist
INSP Inspire Medical
$263.70 /

+3.695 (+1.42%)

  • 12
    Aug
INSP Inspire Medical
$263.70 /

+3.695 (+1.42%)

Conference/Events
Inspire Medical management to meet with Truist » 09:15
03/01/23
03/01
09:15
03/01/23
09:15
INSP

Inspire Medical

$259.92 /

-3.9301 (-1.49%)

Meetings to be held in…

Meetings to be held in New York March 1-2 hosted by Truist.

ShowHide Related Items >><<
INSP Inspire Medical
$259.92 /

-3.9301 (-1.49%)

INSP Inspire Medical
$259.92 /

-3.9301 (-1.49%)

02/08/23 Lake Street
Inspire Medical price target raised to $305 from $250 at Lake Street
02/08/23 Truist
Inspire Medical price target raised to $330 from $310 at Truist
02/08/23 Piper Sandler
Inspire Medical price target raised to $305 from $300 at Piper Sandler
01/31/23 Truist
Inspire Medical price target raised to $310 from $308 at Truist
INSP Inspire Medical
$259.92 /

-3.9301 (-1.49%)

  • 12
    Aug
INSP Inspire Medical
$259.92 /

-3.9301 (-1.49%)

Over a month ago
Recommendations
Inspire Medical price target raised to $305 from $250 at Lake Street » 09:17
02/08/23
02/08
09:17
02/08/23
09:17
INSP

Inspire Medical

$249.33 /

+5.91 (+2.43%)

Lake Street analyst Frank…

Lake Street analyst Frank Takkinen raised the firm's price target on Inspire Medical to $305 from $250 and keeps a Buy rating on the shares, stating that the company "performed superbly" in its "seasonally strongest quarter of the year." Inspire "remains in the early innings" as indicated by the expectation for continued outsized growth and 2023 year-over-year growth guidance of 37%-40%, Lake Street added.

ShowHide Related Items >><<
INSP Inspire Medical
$249.33 /

+5.91 (+2.43%)

INSP Inspire Medical
$249.33 /

+5.91 (+2.43%)

02/08/23 Truist
Inspire Medical price target raised to $330 from $310 at Truist
02/08/23 Piper Sandler
Inspire Medical price target raised to $305 from $300 at Piper Sandler
01/31/23 Truist
Inspire Medical price target raised to $310 from $308 at Truist
01/31/23 Lake Street
CVRx initiated with a Buy at Lake Street
INSP Inspire Medical
$249.33 /

+5.91 (+2.43%)

  • 12
    Aug
INSP Inspire Medical
$249.33 /

+5.91 (+2.43%)

Recommendations
Inspire Medical price target raised to $330 from $310 at Truist » 07:45
02/08/23
02/08
07:45
02/08/23
07:45
INSP

Inspire Medical

$249.33 /

+5.91 (+2.43%)

Truist analyst Richard…

Truist analyst Richard Newitter raised the firm's price target on Inspire Medical to $330 from $310 and keeps a Buy rating on the shares. The company's Q4 marked a "solid beat" and its outlook likely leaves room for upside, the analyst tells investors in a research note, also noting that the stock remains the firm's top FY23 pick. The firm adds that Inspire's monthly its total addressable market.

ShowHide Related Items >><<
INSP Inspire Medical
$249.33 /

+5.91 (+2.43%)

INSP Inspire Medical
$249.33 /

+5.91 (+2.43%)

02/08/23 Piper Sandler
Inspire Medical price target raised to $305 from $300 at Piper Sandler
01/31/23 Truist
Inspire Medical price target raised to $310 from $308 at Truist
01/31/23 Lake Street
CVRx initiated with a Buy at Lake Street
01/26/23 Piper Sandler
Inspire Medical price target raised to $300 from $285 at Piper Sandler
INSP Inspire Medical
$249.33 /

+5.91 (+2.43%)

  • 12
    Aug
INSP Inspire Medical
$249.33 /

+5.91 (+2.43%)

Recommendations
Inspire Medical price target raised to $305 from $300 at Piper Sandler » 04:30
02/08/23
02/08
04:30
02/08/23
04:30
INSP

Inspire Medical

$249.33 /

+5.91 (+2.43%)

Piper Sandler analyst…

Piper Sandler analyst Adam Maeder raised the firm's price target on Inspire Medical to $305 from $300 and keeps an Overweight rating on the shares. The company reported Q4 results with sales at the high-end of the preannouncement and earnings materially better than forecasts, the analyst tells investors in a research note. Piper says Inspire "brings substantial momentum into the new year" and it continues to view the stock as its favorite name in 2023.

ShowHide Related Items >><<
INSP Inspire Medical
$249.33 /

+5.91 (+2.43%)

INSP Inspire Medical
$249.33 /

+5.91 (+2.43%)

01/31/23 Truist
Inspire Medical price target raised to $310 from $308 at Truist
01/31/23 Lake Street
CVRx initiated with a Buy at Lake Street
01/26/23 Piper Sandler
Inspire Medical price target raised to $300 from $285 at Piper Sandler
12/13/22 Goldman Sachs
Inspire Medical upgraded to Buy, named top Medtech midcap at Goldman Sachs
INSP Inspire Medical
$249.33 /

+5.91 (+2.43%)

  • 12
    Aug
INSP Inspire Medical
$249.33 /

+5.91 (+2.43%)

Earnings
Inspire Medical reports Q4 EPS 10c, consensus (57c) » 16:10
02/07/23
02/07
16:10
02/07/23
16:10
INSP

Inspire Medical

$249.92 /

+6.5 (+2.67%)

Reports Q revenue…

Reports Q revenue $137.9M, consensus $129.26M.Net income was $3.2M for the fourth quarter of 2022, as compared to a loss of $2.4M in the corresponding prior year period. The diluted income per share for the fourth quarter of 2022 was $ 10c, as compared to the diluted loss per share of 9c in the prior year period. "We are pleased with our strong performance in the fourth quarter and full year 2022. Our growth in the fourth quarter, as well as for the year, was primarily driven by higher utilization at existing centers and the addition of 61 newU.S. implanting centers and 16 new U.S. sales territories. With significant momentum and many accomplishments throughout our business, we are proud to achieve our first profitable quarter," said Tim Herbert, President and Chief Executive Officer of Inspire Medical Systems. "Given our strong performance in 2022, we are providing 2023 revenue guidance of between $560 million to $570 million, an increase of 37% to 40% year-over-year.""We completed several important milestones in 2022 including an expanded label for full-body MRI compatibility, the commercial launches of our Bluetooth(R)-enabled patient remote and our silicone-based stimulation and sensing leads, the FDA submission of our SleepSync programmer, and important indication expansions for Pediatric Down Syndrome and higher AHI and BMI. We completed enrollment of 300 patients in our PREDICTOR study which aims to remove the drug-induced sleep endoscopy requirement for most patients with BMI under 32. We also made strategic investments in EnsoData and Ognomy and initiated a pilot of a digital scheduling tool to facilitate and streamline patient access to care through our Advisor Care Program," concluded Mr. Herbert.

ShowHide Related Items >><<
INSP Inspire Medical
$249.92 /

+6.5 (+2.67%)

INSP Inspire Medical
$249.92 /

+6.5 (+2.67%)

01/31/23 Truist
Inspire Medical price target raised to $310 from $308 at Truist
01/31/23 Lake Street
CVRx initiated with a Buy at Lake Street
01/26/23 Piper Sandler
Inspire Medical price target raised to $300 from $285 at Piper Sandler
12/13/22 Goldman Sachs
Inspire Medical upgraded to Buy, named top Medtech midcap at Goldman Sachs
INSP Inspire Medical
$249.92 /

+6.5 (+2.67%)

  • 12
    Aug
INSP Inspire Medical
$249.92 /

+6.5 (+2.67%)

On The Fly
Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations » 10:08
01/31/23
01/31
10:08
01/31/23
10:08
FLT

FleetCor

$203.84 /

+2.75 (+1.37%)

, FGEN

FibroGen

$22.62 /

+1.01 (+4.67%)

, LYB

LyondellBasell

$95.78 /

+1.3 (+1.38%)

, NFE

New Fortress Energy

$37.70 /

+0.45 (+1.21%)

, INTR

Inter&Co

$2.69 /

+0.17 (+6.75%)

, PARA

Paramount

$22.40 /

-0.215 (-0.95%)

, EW

Edwards Lifesciences

$76.00 /

-0.125 (-0.16%)

, MDT

Medtronic

$82.83 /

+0.23 (+0.28%)

, BAC

Bank of America

$35.13 /

-0.18 (-0.51%)

, TFC

Truist Financial

$48.38 /

-0.06 (-0.12%)

, NUS

Nu Skin

$41.52 /

-0.78 (-1.84%)

, META

Meta Platforms

$148.95 /

+1.905 (+1.30%)

, INCY

Incyte

$84.95 /

+1.26 (+1.51%)

, FOXA

Fox Corp.

$33.70 /

+0.06 (+0.18%)

, XMTR

Xometry

$33.99 /

+1.28 (+3.91%)

, CVRX

CVRx

$15.08 /

+0.4 (+2.72%)

, INSP

Inspire Medical

$256.10 /

+5.41 (+2.16%)

Institutional investors…

ShowHide Related Items >><<
XMTR Xometry
$33.99 /

+1.28 (+3.91%)

TFC Truist Financial
$48.38 /

-0.06 (-0.12%)

PARA Paramount
$22.40 /

-0.215 (-0.95%)

NUS Nu Skin
$41.52 /

-0.78 (-1.84%)

NFE New Fortress Energy
$37.70 /

+0.45 (+1.21%)

META Meta Platforms
$148.95 /

+1.905 (+1.30%)

MDT Medtronic
$82.83 /

+0.23 (+0.28%)

LYB LyondellBasell
$95.78 /

+1.3 (+1.38%)

INTR Inter&Co
$2.69 /

+0.17 (+6.75%)

INSP Inspire Medical
$256.10 /

+5.41 (+2.16%)

INCY Incyte
$84.95 /

+1.26 (+1.51%)

FOXA Fox Corp.
$33.70 /

+0.06 (+0.18%)

FLT FleetCor
$203.84 /

+2.75 (+1.37%)

FGEN FibroGen
$22.62 /

+1.01 (+4.67%)

EW Edwards Lifesciences
$76.00 /

-0.125 (-0.16%)

CVRX CVRx
$15.08 /

+0.4 (+2.72%)

BAC Bank of America
$35.13 /

-0.18 (-0.51%)

FLT FleetCor
$203.84 /

+2.75 (+1.37%)

01/31/23 BofA
FleetCor upgraded to Buy at BofA as risks get addressed 'head on'
01/31/23 BofA
FleetCor upgraded to Buy from Neutral at BofA
01/25/23 Baird
FleetCor price target raised to $230 from $220 at Baird
01/20/23 Truist
Wex price target raised to $190 from $170 at Truist
FGEN FibroGen
$22.62 /

+1.01 (+4.67%)

01/30/23 William Blair
FibroGen upgraded to Outperform at William Blair on pamrevlumab's potential
01/30/23 William Blair
FibroGen upgraded to Outperform from Market Perform at William Blair
01/26/23 Raymond James
FibroGen upgraded to Outperform from Market Perform at Raymond James
01/26/23 Raymond James
FibroGen upgraded to Outperform from Market Perform at Raymond James
LYB LyondellBasell
$95.78 /

+1.3 (+1.38%)

01/31/23 Atlantic Equities
LyondellBasell upgraded to Overweight from Neutral at Atlantic Equities
01/17/23 Fermium Research
LyondellBasell downgraded to Hold from Buy at Fermium Research
01/17/23 Fermium Research
Dow Inc. downgraded to Hold from Buy at Fermium Research
01/12/23 KeyBanc
LyondellBasell price target raised to $83 from $65 at KeyBanc
NFE New Fortress Energy
$37.70 /

+0.45 (+1.21%)

01/31/23 BTIG
New Fortress Energy upgraded to Buy from Neutral at BTIG
11/16/22 Barclays
New Fortress Energy price target raised to $53 from $48 at Barclays
10/19/22 Jefferies
New Fortress Energy initiated with a Buy at Jefferies
10/19/22 Barclays
New Fortress Energy price target lowered to $48 from $54 at Barclays
INTR Inter&Co
$2.69 /

+0.17 (+6.75%)

01/31/23 Goldman Sachs
Inter&Co upgraded to Buy from Neutral at Goldman Sachs
12/08/22 Grupo Santander
Inter&Co downgraded to Neutral from Outperform at Grupo Santander
09/06/22 Goldman Sachs
Inter&Co upgraded to Neutral from Sell at Goldman Sachs
07/06/22 New Street
Inter&Co initiated with a Neutral at New Street after listing moved to U.S.
PARA Paramount
$22.40 /

-0.215 (-0.95%)

01/31/23 Macquarie
Paramount downgraded to Underperform at Macquarie on high ad exposure
01/31/23 Macquarie
Paramount downgraded to Underperform from Neutral at Macquarie
01/12/23 Guggenheim
Paramount price target raised to $22 from $20 at Guggenheim
01/04/23 Macquarie
Paramount price target lowered to $15 from $16 at Macquarie
EW Edwards Lifesciences
$76.00 /

-0.125 (-0.16%)

01/31/23 Bernstein
Edwards Lifesciences downgraded to Underperform from Outperform at Bernstein
01/30/23 Piper Sandler
Edwards Lifesciences downgraded to Neutral from Overweight at Piper Sandler
12/12/22 Canaccord
Edwards Lifesciences price target lowered to $73 from $78 at Canaccord
12/12/22 Citi
Edwards Lifesciences price target lowered to $92 from $99 at Citi
MDT Medtronic
$82.83 /

+0.23 (+0.28%)

01/24/23 Mizuho
Medtronic price target lowered to $95 from $100 at Mizuho
01/09/23 RBC Capital
Medtronic downgraded to Sector Perform from Outperform at RBC Capital
11/30/22 Wells Fargo
Medtronic price target lowered to $77 from $82 at Wells Fargo
BAC Bank of America
$35.13 /

-0.18 (-0.51%)

01/31/23 Atlantic Equities
Bank of America downgraded to Neutral from Overweight at Atlantic Equities
01/24/23 BofA
Banks' potential new online wallet unlikely to threaten PayPal, says BofA
01/17/23 Citi
Bank of America price target raised to $38 from $36 at Citi
01/17/23 Piper Sandler
Bank of America downgraded to Underweight from Neutral at Piper Sandler
TFC Truist Financial
$48.38 /

-0.06 (-0.12%)

01/31/23 Stephens
Truist Financial downgraded to Equal Weight at Stephens following outperformance
01/31/23 Stephens
Truist Financial downgraded to Equal Weight from Overweight at Stephens
01/09/23 Jefferies
Truist Financial upgraded to Buy from Hold at Jefferies
01/06/23 Deutsche Bank
Truist downgraded to Hold with $48 target at Deutsche Bank
NUS Nu Skin
$41.52 /

-0.78 (-1.84%)

01/31/23 Jefferies
Nu Skin downgraded to Hold at Jefferies on China execution uncertainty
01/30/23 Jefferies
Nu Skin downgraded to Hold from Buy at Jefferies
12/20/22 DA Davidson
Nu Skin price target raised to $40 from $34 at DA Davidson
11/23/22 DA Davidson
Nu Skin price target lowered to $34 from $40 at DA Davidson
META Meta Platforms
$148.95 /

+1.905 (+1.30%)

01/31/23 LightShed Partners
Meta Platforms initiated with a Buy at LightShed Partners
01/30/23 DA Davidson
DA Davidson neutral on Pinterest ahead of earnings
01/27/23 BofA
BuzzFeed still a 'show me story,' Meta deal not new, says BofA
01/26/23 Piper Sandler
Meta Platforms price target raised to $136 from $116 at Piper Sandler
INCY Incyte
$84.95 /

+1.26 (+1.51%)

01/31/23 Piper Sandler
Incyte initiated with an Overweight at Piper Sandler
10/24/22 JPMorgan
Incyte price target lowered to $80 from $86 at JPMorgan
08/03/22 Evercore ISI
Incyte downgraded to In Line from Outperform at Evercore ISI
08/03/22 Guggenheim
Incyte downgraded to Neutral at Guggenheim after Opzelura Q2 miss
FOXA Fox Corp.
$33.70 /

+0.06 (+0.18%)

01/31/23 Morgan Stanley
Fox Corp. resumed with an Equal Weight at Morgan Stanley
01/25/23 Loop Capital
Fox upgraded to Buy with $40 price target at Loop Capital
01/25/23 Loop Capital
Loop upgrades News Corp. to Buy on ending of Fox tie-up
01/25/23 Loop Capital
Fox Corp. upgraded to Buy from Hold at Loop Capital
XMTR Xometry
$33.99 /

+1.28 (+3.91%)

01/31/23 Craig-Hallum
Xometry initiated with a Buy at Craig-Hallum
12/14/22 Lake Street
Xometry initiated with a Sell at Lake Street
12/13/22 Citi
Xometry initiated with a Buy at Citi
11/11/22 UBS
Xometry price target lowered to $45 from $55 at UBS
CVRX CVRx
$15.08 /

+0.4 (+2.72%)

01/31/23 Lake Street
CVRx initiated with a Buy at Lake Street
01/27/23 Canaccord
CVRx price target lowered to $22 from $23 at Canaccord
01/09/23 Piper Sandler
CVRx price target raised to $18.50 from $14 at Piper Sandler
11/02/22 Piper Sandler
CVRx price target raised to $14 from $10 at Piper Sandler
INSP Inspire Medical
$256.10 /

+5.41 (+2.16%)

01/31/23 Truist
Inspire Medical price target raised to $310 from $308 at Truist
01/26/23 Piper Sandler
Inspire Medical price target raised to $300 from $285 at Piper Sandler
12/13/22 Goldman Sachs
Inspire Medical upgraded to Buy, named top Medtech midcap at Goldman Sachs
XMTR Xometry
$33.99 /

+1.28 (+3.91%)

TFC Truist Financial
$48.38 /

-0.06 (-0.12%)

PARA Paramount
$22.40 /

-0.215 (-0.95%)

NUS Nu Skin
$41.52 /

-0.78 (-1.84%)

NFE New Fortress Energy
$37.70 /

+0.45 (+1.21%)

META Meta Platforms
$148.95 /

+1.905 (+1.30%)

MDT Medtronic
$82.83 /

+0.23 (+0.28%)

LYB LyondellBasell
$95.78 /

+1.3 (+1.38%)

INSP Inspire Medical
$256.10 /

+5.41 (+2.16%)

INCY Incyte
$84.95 /

+1.26 (+1.51%)

FOXA Fox Corp.
$33.70 /

+0.06 (+0.18%)

FLT FleetCor
$203.84 /

+2.75 (+1.37%)

FGEN FibroGen
$22.62 /

+1.01 (+4.67%)

EW Edwards Lifesciences
$76.00 /

-0.125 (-0.16%)

CVRX CVRx
$15.08 /

+0.4 (+2.72%)

BAC Bank of America
$35.13 /

-0.18 (-0.51%)

  • 15
    Dec
  • 12
    Aug
XMTR Xometry
$33.99 /

+1.28 (+3.91%)

TFC Truist Financial
$48.38 /

-0.06 (-0.12%)

PARA Paramount
$22.40 /

-0.215 (-0.95%)

NFE New Fortress Energy
$37.70 /

+0.45 (+1.21%)

META Meta Platforms
$148.95 /

+1.905 (+1.30%)

MDT Medtronic
$82.83 /

+0.23 (+0.28%)

FOXA Fox Corp.
$33.70 /

+0.06 (+0.18%)

BAC Bank of America
$35.13 /

-0.18 (-0.51%)

XMTR Xometry
$33.99 /

+1.28 (+3.91%)

TFC Truist Financial
$48.38 /

-0.06 (-0.12%)

PARA Paramount
$22.40 /

-0.215 (-0.95%)

NFE New Fortress Energy
$37.70 /

+0.45 (+1.21%)

META Meta Platforms
$148.95 /

+1.905 (+1.30%)

MDT Medtronic
$82.83 /

+0.23 (+0.28%)

LYB LyondellBasell
$95.78 /

+1.3 (+1.38%)

INCY Incyte
$84.95 /

+1.26 (+1.51%)

FOXA Fox Corp.
$33.70 /

+0.06 (+0.18%)

FLT FleetCor
$203.84 /

+2.75 (+1.37%)

FGEN FibroGen
$22.62 /

+1.01 (+4.67%)

EW Edwards Lifesciences
$76.00 /

-0.125 (-0.16%)

BAC Bank of America
$35.13 /

-0.18 (-0.51%)

TFC Truist Financial
$48.38 /

-0.06 (-0.12%)

PARA Paramount
$22.40 /

-0.215 (-0.95%)

NFE New Fortress Energy
$37.70 /

+0.45 (+1.21%)

META Meta Platforms
$148.95 /

+1.905 (+1.30%)

MDT Medtronic
$82.83 /

+0.23 (+0.28%)

LYB LyondellBasell
$95.78 /

+1.3 (+1.38%)

INTR Inter&Co
$2.69 /

+0.17 (+6.75%)

INCY Incyte
$84.95 /

+1.26 (+1.51%)

FOXA Fox Corp.
$33.70 /

+0.06 (+0.18%)

EW Edwards Lifesciences
$76.00 /

-0.125 (-0.16%)

BAC Bank of America
$35.13 /

-0.18 (-0.51%)

Recommendations
Inspire Medical price target raised to $310 from $308 at Truist » 09:12
01/31/23
01/31
09:12
01/31/23
09:12
INSP

Inspire Medical

$250.95 /

-2.8 (-1.10%)

Truist analyst Richard…

Truist analyst Richard Newitter raised the firm's price target on Inspire Medical to $310 from $308 and keeps a Buy rating on the shares a part of a broader research note previewing Q4 earnings in MedTech. The stock is the firm's "highest conviction beat and raise" forecast after the company pre-announced Q4 revenue last month and as its U.S. monthly utilization again accelerated, the analyst tells investors in a research note. As long as Inspire's growth remains on an accelerating trajectory, the stock's multiple can be sustained with estimates that have big upward revision potential, Truist adds.

ShowHide Related Items >><<
INSP Inspire Medical
$250.95 /

-2.8 (-1.10%)

INSP Inspire Medical
$250.95 /

-2.8 (-1.10%)

01/31/23 Lake Street
CVRx initiated with a Buy at Lake Street
01/26/23 Piper Sandler
Inspire Medical price target raised to $300 from $285 at Piper Sandler
12/13/22 Goldman Sachs
Inspire Medical upgraded to Buy, named top Medtech midcap at Goldman Sachs
12/13/22 Goldman Sachs
Inspire Medical upgraded to Buy from Neutral at Goldman Sachs
INSP Inspire Medical
$250.95 /

-2.8 (-1.10%)

  • 12
    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.